Atlas Trials

Hereditary Inclusion Body Myopathy

8 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hereditary Inclusion Body Myopathy

RecordFirmDate
Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (NCT02736188)Ultragenyx Pharmaceutical Inc2016-05-02
A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment (NCT02731690)Ultragenyx Pharmaceutical Inc2016-04-29
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (NCT02377921)Ultragenyx Pharmaceutical Inc2015-05-20
International GNE Myopathy Patient Registry (NCT04009226)Newcastle University2014-03-01
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) (NCT01784679)Ultragenyx Pharmaceutical Inc2013-04-05
A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (NCT01517880)Ultragenyx Pharmaceutical Inc2012-05-01
Pharmacokinetic Study on N-acetylneuraminic Acid (NCT01236898)Tohoku University2010-11-01
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy (NCT00195637)National Human Genome Research Institute (NHGRI)2005-09-16

Track Hereditary Inclusion Body Myopathy automatically

Every clearance here is in the API, with alerts when new ones post.